BeiGene Presents Updated Results from Phase 3 RATIONALE-309 Trial of PD-1 Inhibitor Tislelizumab in First-Line RM-NPC in Virtual ASCO Plenary Series
Progression-Free Survival Benefit of Tislelizumab in Combination with Chemotherapy Sustained at Median 15.5 Month Follow-up…